Branched-chain amino acids (BCAAs) may also be used as part of treatment, but they work in a different way. People with cirrhosis often have low levels of BCAAs. Taking BCAA supplements can help ...

Dr. Derek van Amerongen introduces a panel discussing hepatic encephalopathy (HE), noting that 30-40% of cirrhotic patients develop overt HE. Dr. Arun Jesudian explains that hepatic encephalopathy (HE ...

Early hepatic encephalopathy following transjugular intrahepatic portosystemic shunt (TIPS) insertion, especially within the first 30 days, was associated with reduced survival in patients with liver ...

Over 6 months, 23.2% of patients receiving rifaximin monotherapy experienced an OHE breakthrough episode compared with 49% of patients receiving lactulose monotherapy (P<0.0001), reported Jasmohan S.

Urease-positive Streptococcus salivarius was the most significantly abundant gut microbiota in patients with HE. Certain gut microbiota are strongly associated with the pathophysiology of hepatic ...

Abstract Background Hepatic encephalopathy is a chronically debilitating complication of hepatic cirrhosis. The efficacy of rifaximin, a minimally absorbed antibiotic, is well documented in the ...

Cirrhosis is the result of long-term liver injury where healthy tissue is replaced with scar tissue (fibrosis). Common causes of cirrhosis include alcohol use disorder (AUD), nonalcoholic fatty liver ...